Introduction
Chronic immune thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by the production of antiplatelet antibodies that bind to platelet surface membrane proteins, resulting in platelet destruction. Approximately 75% of these autoantibodies bind to platelet antigens that lie on either platelet glycoprotein (GP) IIb/IIIa (␣ IIb ␤ 3 ) or GPIb/IX. 1, 2 In the current study, we evaluated the binding of plateletassociated anti-␣ IIb ␤ 3 antibodies from ITP patients to Chinese hamster ovary (CHO) cells expressing either ␣ IIb ␤ 3 or the vitronectin receptor, ␣ v ␤ 3 . Because these 2 integrins have the same beta chain (␤ 3 ), it allowed us to evaluate the relative importance of ␣ IIb and ␤ 3 as sites of auto-epitopes in chronic ITP.
Study design
Samples were obtained from 14 patients with chronic ITP who had high-titer autoantibodies to platelet ␣ IIb ␤ 3 , 2 patients with high-titer anti-GPIb/IX antibodies (one with chronic ITP and one with a drug [procainamide]-dependent antibody), and one patient with posttransfusion purpura who had anti-␤ 3 alloantibodies. Platelets from 3 normal subjects were obtained as controls.
Platelet-associated and plasma antibody eluates were prepared by acid elution as previously described. 3 Before use in the binding assay, the eluates were ultracentrifuged for 30 minutes at 20 000 rpm and pre-adsorbed with untransfected CHO cells (2 ϫ 10 7 cells/mL eluate) to prevent nonspecific binding.
The ␣ IIb ␤ 3 complex-specific monoclonal antibody (mAb) AP2 was provided by Dr Thomas Kunicki (The Scripps Research Institute, La Jolla, CA), and the ␣ v -specific mAb LM142 was obtained from Chemicon (Temecula, CA).
Stably transfected CHO cell lines expressing wild-type ␣ IIb ␤ 3 or ␣ v ␤ 3 have been described previously. 4 Briefly, full-length cDNAs for ␣ IIb , ␣ v , and ␤ 3 were subcloned into the vector CDM8, and CHO cells were cotransfected with the appropriate ␣ subunit (␣ IIb or ␣ v ) and ␤ 3 . The expressed receptors were detected, and clonal cell lines were established with the use of fluorescence-activated cell sorting (FACS) with appropriate monoclonal antibodies. Expression of both the ␣ and ␤ chains was confirmed using appropriate mAbs and FACS.
The CHO cells were harvested from tissue culture flasks with 0.05% trypsin-0.53 mM EDTA in Hank's balanced salt solution. After centrifugation for 5 minutes at 200g, the cells were resuspended in 10 mL Tyrode FACS buffer (0.137 M NaCl, 12 mM NaHCO 3 , 2.6 mM KCl, 2 mM CaCl 2 , 2 mM MgCl 2 , 0.1% bovine serum albumin, 0.1% dextrose, and 5 mM HEPES) containing 0.2 mg/mL soybean trypsin inhibitor and 0.2% fetal calf serum. After 2 washes in Tyrode FACS buffer, the cells were resuspended to a concentration of 10 7 /mL. Each eluate was incubated separately with A5 cells (expressing ␣ IIb ␤ 3 ), B10 cells (expressing ␣ v ␤ 3 ), or nontransfected CHO cells. Fifty-microliter aliquots of CHO cell suspension (5 ϫ 10 5 cells) were transferred to the required number of v-bottom microtiter wells. Autoantibody eluate (175 L) or monoclonal antibody (100 L of either 15 g/mL, if purified, or 1:1000 dilution, if ascites) was added, and the mixture was incubated overnight at 4°C. After 3 washes in Tyrode FACS buffer, the pellets were resuspended in either 100 L fluorescein isothiocyanateconjugated goat antihuman IgG or 100 L FITC-conjugated goat antimouse IgG (Vector Laboratories, Burlingame, CA) at a concentration of 15 g/mL. After a 30-minute incubation on ice and 3 washes, the cells were resuspended in Tyrode FACS buffer and analyzed on a Facscalibur (Becton Dickinson, Mountain View, CA).
Results and discussion
We studied platelet eluates from 15 patients with chronic ITP. Clinical details and antiplatelet antibody results are summarized in Table 1 . There were 9 female and 6 male patients whose ages ranged from 20 to 70 years. Five patients had other autoimmune disorders, such as antiphospholipid syndrome (patients ITP-4 and -5), autoimmune hemolytic anemia (patients ITP-5, -8, -9) and Crohn disease of the colon (patient ITP-6). Thirteen of the 15 ITP patients had undergone splenectomy, and all had relapses after surgery. Fourteen patients had high-titer anti-␣ IIb ␤ 3 antibodies, and one of these also had anti-GPIb/IX antibodies (patient ITP-9). The remaining ITP patient (patient ITP-15) had only anti-GPIb/IX antibodies. In addition, we studied platelet eluates from one patient with an anti-GPIb/IX drug antibody (procainamide), one patient with posttransfusion purpura caused by anti-Pl A1 alloantibodies, and 3 control subjects.
Platelet eluates that had been preadsorbed with untransfected CHO cells were incubated with CHO cells expressing ␣ IIb ␤ 3 , CHO cells expressing ␣ v ␤ 3 , or untransfected CHO cells. Antibody binding was determined by flow cytometry. Representative studies are shown in Figure 1 . Of the 14 platelet eluates from patients with chronic ITP with high-titer autoantibodies to ␣ IIb ␤ 3 , 13 bound only to CHO cells expressing ␣ IIb ␤ 3 . The remaining platelet eluate (patient ITP-6) bound to CHO cells expressing either ␣ IIb ␤ 3 or ␣ v ␤ 3 . Eluates from 3 normal subjects and from the 2 patients with anti-GPIb/IX antibodies (ITP-15 and the patient with the drug-dependent antibody) showed no binding to either of the CHO cell lines. The eluted alloantibody from the patient with posttransfusion purpura and anti-␤ 3 alloantibodies bound to both ␣ IIb ␤ 3 and ␣ v ␤ 3 transfected CHO cells as expected because both expressed ␤ 3 .
These results indicate that anti-␣ IIb ␤ 3 autoantibodies from most patients with chronic ITP (13 of 14) bind to epitopes localized on ␣ IIb . Although it is likely that association with ␤ 3 is required for the proper folding of ␣ IIb and epitope formation, it is clear from these studies that binding of these 13 autoantibodies to antigen does not occur in the absence of ␣ IIb or in the presence of ␤ 3 coupled to ␣ v . One autoantibody, from patient ITP-6, bound to both ␣ IIb ␤ 3 -and ␣ v ␤ 3 -expressing cells, indicating that either (1) the autoepitope is dependent on the presence of ␤ 3 , (2) the autoepitope is present on both ␣ IIb and ␣ v because these molecules are partially homologous, or (3) the patient has multiple autoantibodies with some binding to ␣ IIb and others to ␣ v . Additional studies will be needed to clarify this.
These findings are consistent with previous results from this laboratory. In earlier studies, we produced a series of large peptides spanning the human ␤ 3 molecule and evaluated the ability of autoantibodies from patients with chronic ITP to bind to these peptides. Platelet-associated autoantibodies from only one of 33 patients with ITP showed convincing binding to any of these ␤ 3 peptides. 3 Earlier studies have also shown that many ITP auto-epitopes are cation dependent. 5, 6 The formation of configurational epitopes, caused by cation-dependent folding, could depend on one or more of the 4 calcium-binding regions on ␣ IIb or to the cation-dependent molecular relations between ␣ IIb and ␤ 3 required for complex formation. Future studies, using CHO cells expressing chimeric ␣ IIb-␣ v ␤ 3 molecules, should help us to further localize these auto-epitopes. *Polystyrene beads coated with mAb against either ␣IIb␤3 or GPIb/IX and blocked with bovine serum albumin were incubated with solubilized platelet lysate from either patients or control subjects. Bound immune complexes were detected with radiolabeled anti-IgG. Results are expressed as ratio:cpm anti-IgG bound to patient sample/mean cpm bound to 3 control samples (normal Ͻ2.0). 7 ITP, immune thrombocytopenic purpura; Drug-Ab, drug-dependent (procainamide) antibody; PTP, posttransfusion purpura; APL, antiphospholipid syndrome; AIHA, autoimmune hemolytic anemia; CD, Crohn disease of the colon.
